Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications such as Wegovy and Zepbound, a move that could significantly disrupt pricing in the weight loss drug market. 

The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally.

Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit. 

The selloff came as investors repriced risk across equities amid fears of persistently higher rates, sparked by soft demand at the 20-year Treasury auction.

Looking back on healthcare technology stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Hims & Hers Health (NYSE:HIMS) and its peers.

Hims & Hers Health, Inc. stock price action shows strongly bullish signs in May and could be ready to hit new highs before the 2nd half starts.

Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers.

Hims & Hers Health shares fell 4.1% Wednesday morning. Despite the pullback, the stock remains up an impressive 116% over the past month.

HIMS & HERS HEALTH (NYSE:HIMS) meets Minervini’s Trend Template with strong technicals and explosive earnings growth, making it a high-growth momentum candidate.

CEO Andrew Dudum said it was “more than double what we set out for,” thanks to strong investor demand.

Shares of Hims & Hers have gained 29% over the past week. The move higher has been driven by an impressive Q1 earnings report released last week.

Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.

Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us.

A fundamental analysis of (NYSE:HIMS): HIMS & HERS HEALTH INC (NYSE:HIMS) showing high EPS and FCF growth while beating expectations

The proposal, citing a "Most Favored Nation Policy," fueled debate prompted some watchers to question the legality and feasibility of the move, while others speculated on its potential market impact.